Equity
€234,089 ▲ 0.3%
NDC PHARMA has made a profit without a break since 2022.
NDC PHARMA
Lifetime
19 annual accounts with figures on one time axis, 39 filings since 1986peak €440,846 (2025)
€440,846▲ 16.2%
lowest -€25,752 (2021)
€188,352▲ 85.6%
peak €308,038 (2011)
€234,089▲ 0.3%
€538,803▲ 0.7%
peak 3.5 FTE (2016)
3.2 FTEunchanged
Board2 names since 2005
-
Owners
99.33%
Documentsfilings and deeds
29-12-202533 days before the deadline
2025abbreviated format
Gross margin from €379,505 to €440,846Result from €101,503 to €188,352Cash from €180,665 to €105,151
Key points
from the 2025 annual accountsResult
€188,352 ▲ 85.6%
The result rose in 2025 from €101,503 to €188,352.
Turnover
≈ €1.6m estimated
The abbreviated format states no turnover.
Staff
4 employees on 30-06-2025
In 2025, 1 person joined and 1 left.
Filings
39 annual accounts since 1986
The last five annual accounts were filed 0 to 33 days before the end of the period.
Position in the sector
€188,352
Higher net result than 85% of companies in retail trade. Sector median €37,956 · 13,243 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,386 companies had the same profile as NDC PHARMA has now. Each dot stands for 79 companies, two years later.
93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,386 companies, not a prediction for NDC PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
last known boardDirector, until 2024
- 99.33%score equity €516,509 (2025) · 30-06-2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0429465124
Company renamed from SAP-DECLOEDT to NDCPHARMA
Resignations: (director) and (director) · Appointment: (director) · Permanent representative: · General meeting of 20-11-2023 · Gazette deed
Amendment of the articles
Gazette deed
2 directors reappointed
(managing director) and · Permanent representative: · General meeting of 30-06-2016 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| NDC PHARMA Hooglede | €772,892 | €440,846 | 30.3% | 3.2 |
| APOTHEEK VAN OPROY Laakdal | €809,218 | €447,188 | 45.5% | 2.9 |
| APOTHEEK VAN BESIEN Nieuwpoort | €909,462 | €380,090 | 63.1% | 3.8 |
| APOTHEEK M. HEYLEN Bocholt | €713,305 | €485,892 | 16.0% | 3 |
| PASMANS-MERTENS Brasschaat | €842,675 | €455,685 | 41.8% | 2.6 |
| Apoteek Geraerts Hasselt | €660,254 | €359,122 | 72.1% | 3.2 |
| PHARMACIE C. PIRON Liège | €900,485 | €376,767 | 28.2% | 3.6 |
These companies have the same main activity as NDC PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €660,000 and €909,000, founded between 1982 and 1991.
Official details
Source: KBO- Status
- Active since 26-09-1986Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 30-06-2025
- Establishment unit
- 2.034.623.1048830 Hooglede, since 10-11-1986
- Financial year end
- 30 June
- Peppol
- Reachable since 17-03-2025
Annual accounts to 30-06-2025
- €772,892▲ 0.6%
- Employeeson 30-06-2025
- 4=
- Filing
- Filed on 29-12-2025, 33 days before the end of the filing period
Insights on NDC PHARMA
NDC PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €213,173 in 2006 to €440,846 in 2025.
The balance sheet grew most from 2009 to 2011 through fixed assets, financed with long-term debt.
holds 99.33% of the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about NDC PHARMA
- What is the company number of NDC PHARMA?
- The company number of NDC PHARMA is 0429.465.124. The VAT number is the same number with BE in front: BE 0429.465.124.
- Where is NDC PHARMA based?
- The registered office is at Bruggestraat 2, 8830 Hooglede.Company details
- What does NDC PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of NDC PHARMA?
- NDC PHARMA is a public limited company (NV).
- When was NDC PHARMA founded?
- NDC PHARMA was founded on 26-09-1986.
- Is NDC PHARMA still active?
- Yes, NDC PHARMA is an active enterprise in the KBO register.
- How many employees does NDC PHARMA have?
- NDC PHARMA had an average of 3.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does NDC PHARMA fall under?
- In its 30-06-2025 annual accounts, NDC PHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of NDC PHARMA?
- The turnover in financial year 2025 is ≈ €1.6m. This figure is estimated from the gross margin of €440,846 and 47 comparable companies (NACE 477). It probably lies between €1.2m and €2.5m.
- Is NDC PHARMA profitable?
- In financial year 2025, NDC PHARMA made a profit of €188,352.
- Where can I find the annual accounts of NDC PHARMA?
- NDC PHARMA filed 39 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of NDC PHARMA due?
- NDC PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.